Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04540107 · ClinicalTrials.gov registry record · Phase 1
Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma
A Phase 1 study of WHO Grade III Glioma and Recurrent WHO Grade III Glioma, sponsored by Susan Chang.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 300
- Enrollment target
- 1
- Study location
NCT04540107 is a Phase 1 study of WHO Grade III Glioma and Recurrent WHO Grade III Glioma that is actively recruiting participants, run by Susan Chang. The registered enrollment target is 300 participants, above the 122-participant average among 11 other WHO Grade III Glioma trials with a reported enrollment target (146% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04540107, a Phase 1 study of WHO Grade III Glioma and Recurrent WHO Grade III Glioma, is actively recruiting participants, sponsored by Susan Chang.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial studies how well serial magnetic resonance (MR) imaging and MR spectroscopic imaging work in characterizing lower grade glioma. Diagnostic procedures, such as MR imaging and MR spectroscopic imaging, may detect serial changes in lower grade glioma. This study may help researchers learn more about practical ways of evaluating and standardizing treatment in patients with brain tumors.
Conditions Studied
Interventions
- PROCEDURE Magnetic Resonance Imaging
- DRUG Hyperpolarized Carbon C 13 Pyruvate
- PROCEDURE Magnetic Resonance Spectroscopic Imaging
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2017-01-11 |
| Est. Completion | 2027-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04540107
The ClinicalTrials.gov registry entry for NCT04540107 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 122-participant average among 11 other WHO Grade III Glioma trials with a reported enrollment target (146% higher). The listed sponsor is Susan Chang, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with WHO Grade III Glioma appearing as the primary indexed condition, and to 3 interventions - of which Magnetic Resonance Imaging is the first listed.
NCT04540107 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04540107 about?
NCT04540107 is a clinical study titled "Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma". This trial studies how well serial magnetic resonance (MR) imaging and MR spectroscopic imaging work in characterizing lower grade glioma. Diagnostic procedures, such as MR imaging and MR spectroscopic imaging, may detect serial changes in lower grade glioma. This study may help researchers learn mo...
What is the current status of trial NCT04540107?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 300 participants. The study started on 2017-01-11. Estimated completion is 2027-01-31.
What conditions does trial NCT04540107 study?
This clinical trial studies the following conditions: WHO Grade III Glioma, Recurrent WHO Grade III Glioma, WHO Grade II Glioma, Recurrent World Health Organization (WHO) Grade II Glioma.
What interventions are being tested in trial NCT04540107?
The interventions under investigation include: Magnetic Resonance Imaging (PROCEDURE), Hyperpolarized Carbon C 13 Pyruvate (DRUG), Magnetic Resonance Spectroscopic Imaging (PROCEDURE).
Who is sponsoring clinical trial NCT04540107?
This trial is sponsored by Susan Chang, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04540107 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for WHO Grade III Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas
ACTIVE NOT RECRUITING · Phase 1
-
Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma
ACTIVE NOT RECRUITING · Phase 1
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
RECRUITING · Early Phase 1
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.